Mazur Amends Citius Pharma 13D Filing
Ticker: CTXR · Form: SC 13D/A · Filed: Nov 27, 2024 · CIK: 1506251
Sentiment: neutral
Topics: sec-filing, schedule-13d, amendment
Related Tickers: CTRS
TL;DR
Mazur updated his Citius Pharma 13D filing, date of event Nov 25.
AI Summary
Leonard L. Mazur filed an amendment (No. 2) to Schedule 13D on November 27, 2024, regarding Citius Pharmaceuticals, Inc. The filing indicates a change in the date of event requiring this statement to November 25, 2024. Mazur is listed as the person authorized to receive notices and communications for this filing.
Why It Matters
This amendment signals a potential shift in significant ownership or control of Citius Pharmaceuticals, Inc., requiring disclosure to the market.
Risk Assessment
Risk Level: medium — Amendments to Schedule 13D often indicate changes in beneficial ownership or control, which can impact stock price and investor strategy.
Key Players & Entities
- Leonard L. Mazur (person) — Filing person and authorized contact
- Citius Pharmaceuticals, Inc. (company) — Subject company
- November 25, 2024 (date) — Date of event requiring filing
- November 27, 2024 (date) — Filing date
FAQ
What is the specific nature of the change being reported in Amendment No. 2 to Schedule 13D?
The filing does not detail the specific nature of the change, only that it is an amendment to a previously filed Schedule 13D and that the date of the event requiring the filing is November 25, 2024.
Who is Leonard L. Mazur in relation to Citius Pharmaceuticals, Inc.?
Leonard L. Mazur is identified as the person filing the Schedule 13D amendment and is authorized to receive notices and communications regarding the filing.
What is the CUSIP number for Citius Pharmaceuticals, Inc. common stock?
The CUSIP number for Citius Pharmaceuticals, Inc. common stock is 17322U306.
When was the previous Schedule 13D filing for Citius Pharmaceuticals, Inc. by Leonard L. Mazur?
The provided text indicates this is Amendment No. 2, implying previous filings, but does not specify the date of the original or prior amendment.
What is the business address and phone number associated with Leonard L. Mazur for this filing?
The business address is C/O Citius Pharmaceuticals, Inc., 11 Commerce Drive, 1st Floor, Cranford, New Jersey 07016, and the telephone number is (908) 967-6676.
Filing Stats: 1,103 words · 4 min read · ~4 pages · Grade level 8.4 · Accepted 2024-11-27 16:05:31
Key Financial Figures
- $0.001 — INC. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securiti
- $31.25 — ck of the Issuer at a purchase price of $31.25 per share. One third of the options ves
- $17.50 — ck of the Issuer at a purchase price of $17.50 per share. One third of the options ves
- $9.50 — ck of the Issuer at a purchase price of $9.50 per share. One third of the options ves
Filing Documents
- ea0222889-13da2mazur_citius.htm (SC 13D/A) — 33KB
- 0001213900-24-103453.txt ( ) — 35KB
Source and Amount of Funds or Other Consideration
Item 3. Source and Amount of Funds or Other Consideration.
is hereby amended to add the following
Item 3 is hereby amended to add the following: On October 4, 2022, the Reporting Person was granted an option to purchase 22,000 shares of Common Stock of the Issuer at a purchase price of $31.25 per share. One third of the options vest on the first, second and third anniversary of the grant date of October 4, 2022. On October 10, 2023, the Reporting Person was granted an option to purchase 22,000 shares of Common Stock of the Issuer at a purchase price of $17.50 per share. One third of the options vest on the first, second and third anniversary of the grant date of October 10, 2023. On November 7, 2024, the Reporting Person was granted an option to purchase 24,000 shares of Common Stock of the Issuer at a purchase price of $9.50 per share. One third of the options vest on the first, second and third anniversary of the grant date of November 7, 2024.
Interest in Securities of the Issuer
Item 5. Interest in Securities of the Issuer.
is hereby amended to add the following
Item 5 is hereby amended to add the following: (a) The Reporting Person is the beneficial owner of an aggregate of 754,295 shares of the Issuer's Common Stock, which represents approximately 9.3% of the Issuer's outstanding Common Stock, based upon 7,727,243 shares of Common Stock outstanding as of November 25, 2024, as disclosed by the Issuer to the Reporting Person, giving effect to the Reverse Stock Split. The Reporting Person's beneficial ownership consists of (i) 410,214 shares of the Issuer's Common Stock, (ii) 261,481 shares of the Issuer's Common Stock issuable upon the exercise of warrants, and (iii) 82,600 shares of the Issuer's Common Stock subject to options held by the Reporting Person that are exercisable within 60 days of November 25, 2024. The reporting Person holds options to purchase up to an aggerate of 46,000 shares of Common Stock that are not exercisable within 60 days of November 25, 2024. (b) The Reporting Person has sole voting and dispositive power of 754,295 shares of the Issuer's Common Stock beneficially owned. CUSIP No. 17322U306 Page 4 of 4 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: November 27, 2024 /s/ Leonard L. Mazur Leonard L. Mazur